This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hadoke, P. W.F. Articles by Walker, B. R. Search for Related Content PubMed PubMed Citation Articles by Hadoke, P. W.F. Articles by Walker, B. R. Related Collections Other hypertension Endothelium/vascular type/nitric oxide

(Circulation. 2001;104:2832.)
© 2001 American Heart Association, Inc.

Basic Science Reports

Endothelial Cell Dysfunction in Mice After Transgenic Knockout of Type 2, but Not Type 1, 11ß-Hydroxysteroid Dehydrogenase

Patrick W.F. Hadoke, PhD; Clare Christy, BSc; Yuri V. Kotelevtsev, PhD; Brent C. Williams, PhD; Christopher J. Kenyon, PhD; Jonathan R. Seckl, PhD; John J. Mullins, PhD; Brian R. Walker, MD

From the Endocrinology (P.W.F.H., C.C., B.C.W., C.J.K., J.R.S., B.R.W.), Endothelial Cell Biology (Y.V.K.), and Molecular Physiology (J.J.M.) groups, University of Edinburgh, Edinburgh, UK.

Correspondence to Dr Patrick Hadoke, Endocrinology Unit, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK. E-mail phadoke{at}srv0.med.ed.ac.uk

Background— 11ß-Hydroxysteroid dehydrogenase (11ßHSD) isozymes catalyze the interconversion of active and inactive glucocorticoids, allowing local regulation of corticosteroid receptor activation. Both are present in the vessel wall; here, using mice with selective inactivation of 11ßHSD isozymes, we test the hypothesis that 11ßHSDs influence vascular function.

Methods and Results— Thoracic aortas were obtained from weight-matched male wild-type (MF1x129 cross^+/+), 11ßHSD1^-/-, and 11ßHSD2^-/- mice. mRNA for both isozymes was detected in wild-type aortas by RT-PCR. 11ßHSD activity in aortic homogenates (48.81±4.65% conversion) was reduced in both 11ßHSD1^-/- (6.36±2.47% conversion; P<0.0002) and 11ßHSD2^-/- (24.71±3.69; P=0.002) mice. Functional responses were unaffected in aortic rings isolated from 11ßHSD1^-/- mice. In contrast, aortas from 11ßHSD2^-/- mice demonstrated selectively enhanced constriction to norepinephrine (E_max 4.28±0.56 versus 1.72±0.47 mN/mm; P=0.004) attributable to impaired endothelium-derived nitric oxide activity. Relaxation responses to endothelium-dependent and -independent vasodilators were also impaired. To control for chronic renal mineralocorticoid excess, MF1 mice were treated with fludrocortisone (16 weeks) but did not reproduce the functional changes observed in 11ßHSD2^-/- mice.

Conclusions— Although both 11ßHSD isozymes are present in the vascular wall, reactivation of glucocorticoids by 11ßHSD1 does not influence aortic function. Mice with 11ßHSD2 knockout, however, have endothelial dysfunction causing enhanced norepinephrine-mediated contraction. This appears to be independent of renal sodium retention and may contribute to hypertension in 11ßHSD2 deficiency.

Key Words: hydroxysteroid dehydrogenases • hypertension • aorta • endothelium • vasoconstriction

This article has been cited by other articles:

				Y. Liu, D. Mladinov, J. L. Pietrusz, K. Usa, and M. Liang Glucocorticoid response elements and 11{beta}-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression Cardiovasc Res, January 1, 2009; 81(1): 140 - 147. [Abstract] [Full Text] [PDF]

				R. A. De Sousa Peixoto, S. Turban, J. H. Battle, K. E. Chapman, J. R. Seckl, and N. M. Morton Preadipocyte 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Is a Keto-Reductase and Contributes to Diet-Induced Visceral Obesity in Vivo Endocrinology, April 1, 2008; 149(4): 1861 - 1868. [Abstract] [Full Text] [PDF]

				M. A. Bailey, J. M. Paterson, P. W.F. Hadoke, N. Wrobel, C. O.C. Bellamy, D. G. Brownstein, J. R. Seckl, and J. J. Mullins A Switch in the Mechanism of Hypertension in the Syndrome of Apparent Mineralocorticoid Excess J. Am. Soc. Nephrol., January 1, 2008; 19(1): 47 - 58. [Full Text] [PDF]

				M. Myers, M. C. Lamont, S. van den Driesche, N. Mary, K. J. Thong, S. G. Hillier, and W. C. Duncan Role of Luteal Glucocorticoid Metabolism during Maternal Recognition of Pregnancy in Women Endocrinology, December 1, 2007; 148(12): 5769 - 5779. [Abstract] [Full Text] [PDF]

				B. R Walker Glucocorticoids and Cardiovascular Disease Eur. J. Endocrinol., November 1, 2007; 157(5): 545 - 559. [Abstract] [Full Text] [PDF]

				J. S. Gilmour, A. E. Coutinho, J.-F. Cailhier, T. Y. Man, M. Clay, G. Thomas, H. J. Harris, J. J. Mullins, J. R. Seckl, J. S. Savill, et al. Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J. Immunol., June 15, 2006; 176(12): 7605 - 7611. [Abstract] [Full Text] [PDF]

				H. Oberleithner, C. Riethmuller, T. Ludwig, V. Shahin, C. Stock, A. Schwab, M. Hausberg, K. Kusche, and H. Schillers Differential action of steroid hormones on human endothelium. J. Cell Sci., May 1, 2006; 119(Pt 9): 1926 - 1932. [Abstract] [Full Text] [PDF]

				S. K. Paulsen, S. B. Pedersen, J. O. L. Jorgensen, S. Fisker, J. S. Christiansen, A. Flyvbjerg, and B. Richelsen Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1093 - 1098. [Abstract] [Full Text] [PDF]

				B. Kadereit, P. Fustier, K. Shojaati, B. M. Frey, F. J. Frey, and M. G. Mohaupt Extracellular ATP Determines 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Activity via Purinergic Receptors J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3507 - 3516. [Abstract] [Full Text] [PDF]

				J. M. Paterson, J. R. Seckl, and J. J. Mullins Genetic manipulation of 11{beta}-hydroxysteroid dehydrogenases in mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R642 - R652. [Abstract] [Full Text] [PDF]

				G. R. Small, P. W. F. Hadoke, I. Sharif, A. R. Dover, D. Armour, C. J. Kenyon, G. A. Gray, and B. R. Walker Preventing local regeneration of glucocorticoids by 11{beta}-hydroxysteroid dehydrogenase type 1 enhances angiogenesis PNAS, August 23, 2005; 102(34): 12165 - 12170. [Abstract] [Full Text] [PDF]

				P. Meneton, X. Jeunemaitre, H. E. de Wardener, and G. A. Macgregor Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases Physiol Rev, April 1, 2005; 85(2): 679 - 715. [Abstract] [Full Text] [PDF]

				J. W. Tomlinson, E. A. Walker, I. J. Bujalska, N. Draper, G. G. Lavery, M. S. Cooper, M. Hewison, and P. M. Stewart 11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response Endocr. Rev., October 1, 2004; 25(5): 831 - 866. [Abstract] [Full Text] [PDF]

				B. Bocchi, S. Kenouch, M. Lamarre-Cliche, M. Muffat-Joly, M. H. Capron, J. Fiet, G. Morineau, M. Azizi, J. P. Bonvalet, and N. Farman Impaired 11-{beta} Hydroxysteroid Dehydrogenase Type 2 Activity in Sweat Gland Ducts in Human Essential Hypertension Hypertension, April 1, 2004; 43(4): 803 - 808. [Abstract] [Full Text] [PDF]

				C. G. Perry, A. Spiers, S. J. Cleland, G. D. O. Lowe, J. R. Petrie, and J. M. C. Connell Glucocorticoids and Insulin Sensitivity: Dissociation of Insulin's Metabolic and Vascular Actions J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6008 - 6014. [Abstract] [Full Text] [PDF]

				C. Christy, P. W.F. Hadoke, J. M. Paterson, J. J. Mullins, J. R. Seckl, and B. R. Walker 11{beta}-Hydroxysteroid Dehydrogenase Type 2 in Mouse Aorta: Localization and Influence on Response to Glucocorticoids Hypertension, October 1, 2003; 42(4): 580 - 587. [Abstract] [Full Text] [PDF]

				M. Quinkler and P. M. Stewart Hypertension and the Cortisol-Cortisone Shuttle J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2384 - 2392. [Abstract] [Full Text] [PDF]